Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on October 19, 2007
Japanese Journal of Clinical Oncology 2007 37(10):755-762; doi:10.1093/jjco/hym095
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
37/10/755    most recent
hym095v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Akaza, H.
Right arrow Articles by Naito, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Akaza, H.
Right arrow Articles by Naito, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2007 Foundation for Promotion of Cancer Research

Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Sorafenib in Japanese Patients with Advanced Renal Cell Carcinoma

Hideyuki Akaza1, Taiji Tsukamoto2, Masaru Murai3, Keiko Nakajima4 and Seiji Naito5

1 Department of Urology and Andrology, Graduate School of Comprehensive Human Science, University of Tsukuba, Tsukuba, Ibaraki
2 Department of Urology, Sapporo Medical University School of Medicine, Sapporo
3 Department of Urology, Keio University School of Medicine, Tokyo
4 Bayer Yakuhin Ltd, Product Development Division, Osaka
5 Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

For reprints and all correspondence: Hideyuki Akaza, Department of Urology and Andrology, Graduate School of Comprehensive Human Science, University of Tsukuba, Tsukuba 305-8576, Japan. E-mail: akazah{at}md.tsukuba.ac.jp

Received March 7, 2007; accepted June 8, 2007

Objective: Sorafenib (Nexavar®) is an oral multi-kinase inhibitor that targets tumor growth and angiogenesis. This phase II study investigated efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma (RCC).

Methods: Nonrandomized, open-label study in Japanese patients with metastatic renal cell carcinoma who had received nephrectomy and failed ≥1 cytokine-containing therapy. The primary endpoint was response rate. Patients received sorafenib 400 mg twice daily (b.i.d.) on a continuous dosing schedule.

Results: A total of 129 patients (median age 63 years) were valid for intention-to-treat analyses. Confirmed partial responses were observed in 16 (12.4%) patients, and investigators assessed that 19 (14.7%) of the patients achieved a partial response. Stable disease was reported in 93 (72.1%) patients, and 103 (80.5%) patients had tumor shrinkage. Median progression-free survival was 224 days and the 25th percentile of overall survival was estimated at 288 days. The most frequently occurring drug-related adverse events (any grade) were elevated lipase (56%), hand–foot skin reaction (55%), alopecia (39%), increased amylase (38%), rash/desquamation (37%), and diarrhea (34%). A total of 14 (10.7%) patients had serious sorafenib-related adverse events, including one adverse event of worst grade 5 (dyspnea occurred 35 days after the last dose of study medication). The Ctrough,steady state values in RCC patients (n = 63) receiving sorafenib 400 mg b.i.d. were similar to those obtained from a Japanese phase I study involving patients with mixed solid tumors.

Conclusion: Sorafenib showed encouraging efficacy and was well tolerated in Japanese patients with metastatic RCC.

Key Words: sorafenib • Nexavar • BAY 43-9006 • clinical trial • Phase II • renal cell carcinoma • RCC


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
H. Uemura, N. Shinohara, T. Yuasa, Y. Tomita, H. Fujimoto, M. Niwakawa, S. Mugiya, T. Miki, N. Nonomura, M. Takahashi, et al.
A Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma: Insights into the Treatment, Efficacy and Safety
Jpn. J. Clin. Oncol., November 7, 2009; (2009) hyp146v1.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. Thiam, L. S. Fournier, L. Trinquart, J. Medioni, G. Chatellier, D. Balvay, B. Escudier, C. Dromain, C. A. Cuenod, and S. Oudard
Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib
Ann. Onc., November 4, 2009; (2009) mdp466v1.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
R. J. Cersosimo
Renal cell carcinoma with an emphasis on drug therapy of advanced disease, part 1
Am. J. Health Syst. Pharm., September 1, 2009; 66(17): 1525 - 1536.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
M. Iguchi, M. Matsumoto, K. Hojo, T. Wada, Y. Matsuo, A. Arimura, and K. Abe
Antitumor Efficacy of Recombinant Human Interleukin-2 Combined with Sorafenib Against Mouse Renal Cell Carcinoma
Jpn. J. Clin. Oncol., May 1, 2009; 39(5): 303 - 309.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.